Bionano Genomics, Inc. BNGO

Technology SIC 3826 - Laboratory Analytical Instruments NAICS Manufacturing › Computer and Electronic Product Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing › Analytical Laboratory Instrument Manufacturing derived Nasdaq

We are a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping ("OGM") solutions, nucleic acid extraction and purification systems, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. We offer a platform-agnostic software solution, which integrates next-generation sequencing ("NGS"), microarray and OGM data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis ("ITP") technology. Through our Bionano Laboratories business, we also provide OGM-based diagnostic testing services.

Last close 1.13 2026-10-23
Market cap $13.3M 2026-06-30 share count
52-week range 1.00 - 2.23

Valuation FY2025 figures against the last close

P/S0.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-4.85

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • Emea
  • Americas
  • Asia Pacific
Revenue by geography, 3 categories over 2 years. The same figures are in the table below. FY2025 Emea, FY2025: 14.1M (49.5%) 49% Emea Americas, FY2025: 12.2M (42.7%) 43% Americas Asia Pacific, FY2025: 2.2M (7.8%) 8% FY2024 Emea, FY2024: 14.2M (46.3%) 46% Americas, FY2024: 13.6M (44.3%) 44% Asia Pacific, FY2024: 2.9M (9.4%) 9%
Region FY2025FY2024
Emea $14.1M $14.2M
Americas $12.2M $13.6M
Asia Pacific $2.2M $2.9M

As the company reported it, from the “Revenue from Contracts with Customers - Revenue by Source and Geographic Location (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $28.5M$30.8M$36.1M$27.8M$18.0M$8.5M$10.1M$12.0M$9.5M—
Cost of revenue $15.3M$30.4M$26.6M$21.9M$14.1M$5.7M$6.8M$8.7M$6.0M—
Gross profit $13.2M$380.0K$9.6M$5.9M$3.9M$2.8M$3.4M$3.3M$3.5M—
R&D $11.4M$24.8M$54.0M$49.0M$22.5M$10.3M$9.1M$9.5M$12.0M—
SG&A $35.1M$51.9M$92.8M$88.6M$58.5M$31.1M$20.2M$14.2M$14.1M—
Total operating expenses $46.5M$104.4M$224.8M$137.6M$81.0M$41.3M$29.2M$23.7M$26.7M—
Operating income -$33.3M-$104.0M-$215.2M-$131.7M-$77.1M-$38.6M-$25.9M-$20.4M-$23.2M—
Interest expense ——$5.1M$298.0K$927.0K$2.5M$2.3M$1.4M$590.9K—
Pre-tax income -$26.3M-$112.0M-$232.4M-$130.7M-$78.2M-$41.1M-$29.8M-$18.5M-$23.3M—
Income tax $67.0K$33.0K$62.0K$1.9M$5.7M$29.0K$21.0K$15.5K$18.6K—
Net income -$26.4M-$112.0M-$232.5M-$132.6M-$72.4M-$41.1M-$29.8M-$18.5M-$23.4M—
EPS, basic -4.85-88.13-408.60-4.58-0.26—————
EPS, diluted -4.85-88.13-408.60-4.58-0.26-0.39-1.99-2.61-8.65—
Shares, diluted (wtd. avg.) 5.4M1.3M569,00028.9M276.8M—————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $3.0M$9.2M$17.9M$5.1M$24.6M$38.4M$17.3M$16.5M$1.0M—
Short-term investments $16.3M$302.0K$48.8M$108.1M$226.0M$0————
Receivables $5.2M$4.8M$9.3M$7.0M$4.9M$2.8M$6.3M$4.5M$3.4M—
Inventory $7.8M$13.3M$27.6M$29.8M$12.4M$3.3M$3.4M$1.1M$1.7M—
Total current assets $45.4M$39.5M$140.1M$157.3M$272.4M$46.8M$28.3M$23.0M$7.1M—
Property, plant and equipment $14.8M$19.2M$23.3M$18.0M$10.3M$4.9M$1.9M$1.8M$3.0M—
Goodwill ——$0$77.3M$56.2M$7.2M$0———
Other intangibles $4.3M$9.7M$34.0M$41.1M$26.8M$1.5M$0———
Total assets $73.6M$76.7M$214.4M$307.5M$377.1M$60.5M$30.2M$24.8M$10.1M—
Accounts payable $5.6M$7.0M$10.4M$12.5M$10.8M$2.9M$2.7M$1.4M$2.3M—
Short-term debt —————$0$20.1M$0$6.7M—
Total current liabilities $22.9M$37.3M$100.0M$35.9M$21.8M$8.9M$26.4M$4.5M$16.7M—
Long-term debt ————$0$16.3M$0$9.0M$0—
Total liabilities $29.2M$41.3M$118.2M$58.1M$40.0M$25.4M$26.6M$14.7M$17.4M—
Retained earnings -$719.6M-$693.2M-$581.2M-$348.7M-$216.1M-$143.7M-$102.6M-$72.8M-$54.3M—
Total equity $44.4M$35.4M$96.2M$249.4M$337.1M$35.1M$3.6M$10.1M-$50.2M-$27.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$16.3M-$68.9M-$125.2M-$124.8M-$71.9M-$38.3M-$29.5M-$19.9M-$20.8M—
Depreciation and amortisation $9.5M$14.0M$13.7M$9.6M$3.4M$1.5M$1.1M$1.3M$1.5M—
Stock-based compensation $4.5M$9.7M$15.2M$22.4M$9.7M$1.6M$1.3M$1.2M$382.8K—
Capital expenditure —————$0$61.1K$331.7K$1.0M—
Investing cash flow -$12.7M$73.8M$24.2M$82.8M-$278.1M-$2.5M-$61.1K-$331.7K-$1.0M—
Financing cash flow $24.0M-$13.7M$113.8M$23.0M$336.1M$61.9M$30.4M$35.8M$17.6M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001411690-26-000007.

Plot the figures US dollars

  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -300M -200M -100M 0 100M Revenue, FY2017: 9.5M Gross profit, FY2017: 3.5M Net income, FY2017: -23.4M Revenue, FY2018: 12M Gross profit, FY2018: 3.3M Net income, FY2018: -18.5M Revenue, FY2019: 10.1M Gross profit, FY2019: 3.4M Net income, FY2019: -29.8M Revenue, FY2020: 8.5M Gross profit, FY2020: 2.8M Net income, FY2020: -41.1M Revenue, FY2021: 18M Gross profit, FY2021: 3.9M Net income, FY2021: -72.4M Revenue, FY2022: 27.8M Gross profit, FY2022: 5.9M Net income, FY2022: -132.6M Revenue, FY2023: 36.1M Gross profit, FY2023: 9.6M Net income, FY2023: -232.5M Revenue, FY2024: 30.8M Gross profit, FY2024: 380K Net income, FY2024: -112M Revenue, FY2025: 28.5M Gross profit, FY2025: 13.2M Net income, FY2025: -26.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $9.5M $12.0M $10.1M $8.5M $18.0M $27.8M $36.1M $30.8M $28.5M
Gross profit — $3.5M $3.3M $3.4M $2.8M $3.9M $5.9M $9.6M $380.0K $13.2M
Net income — -$23.4M -$18.5M -$29.8M -$41.1M -$72.4M -$132.6M -$232.5M -$112.0M -$26.4M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3826

TickerCompanyMarket capP/ERevenue growth
A AGILENT TECHNOLOGIES, INC. $48.79B 37.9x 6.7%
WAT WATERS CORP /DE/ $44.57B 42.2x 7.0%
ILMN ILLUMINA, INC. $40.68B 49.4x -0.7%
MTD METTLER TOLEDO INTERNATIONAL INC/ $33.47B 39.7x 4.0%
RVTY REVVITY, INC. $17.72B 76.7x 3.7%
AVTR Avantor, Inc. $11.80B — -3.4%
BIO BIO-RAD LABORATORIES, INC. $9.89B 13.3x 0.7%
TXG 10x Genomics, Inc. $9.30B — 5.2%